查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298353

淋巴瘤治療市場：按疾病類型、治療類型、給藥途徑、分銷渠道：2023-2032年全球機會分析和行業預測

Lymphoma Therapeutics Market By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 481 Pages | 商品交期: 2-3個工作天內

價格

2022 年淋巴瘤治療市場價值為 156.9145 億美元，預計 2032 年將達到 352.745 億美元，2023 年至 2032 年復合年增長率為 8.4%。

淋巴瘤是一種影響淋巴系統的癌症，淋巴系統是抵抗感染和其他疾病的免疫系統的一部分。 當一種稱為淋巴細胞的白細胞發生異常變化並開始不受控制地繁殖和生長時，就會發生淋巴瘤。 淋巴瘤治療是指用於治療淋巴瘤的不同類型的治療方法。 各種類型的淋巴瘤治療包括化療、放射治療、免疫治療、靶向治療、幹細胞移植，有時還包括手術。

淋巴瘤治療市場-IMG1

推動淋巴瘤治療市場增長的主要因素是淋巴瘤治療藥物管道的不斷增加。 例如，根據 2023 年 3 月的 GlobalData 報告，拜耳的硫酸拉羅替尼正處於非霍奇金淋巴瘤的臨床開發階段，目前處於 II 期階段。 非霍奇金淋巴瘤 II 期藥物的階段轉移成功率 (PTSR) 為 40%，這是進展至 III 期的標誌。

此外，淋巴瘤患病率的顯著增加和老年人口的迅速增加也對市場增長做出了重大貢獻。 此外，研發活動投資的增加以及政府批准治療非霍奇金淋巴瘤和霍奇金淋巴瘤新藥的優惠政策預計將為預測期內全球市場的增長開闢新的途徑。

然而，現有治療方法的高成本、對淋巴瘤的認識低以及治療淋巴瘤的不同選擇的可用性阻礙了市場的增長。 相反，易患淋巴瘤的老年人口的迅速增加以及對患者友好、安全有效的藥物的開發預計將為預測期內的市場增長提供利潤豐厚的機會。

內容

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 協調員
      • 淋巴瘤激增
      • 正在研發的藥物數量增加
      • 臨床試驗數量增加
    • 阻礙因素
      • 現有治療費用高昂
    • 機會
      • 新興經濟體的高增長潛力
  • COVID-19：市場影響分析

第 4 章淋巴瘤治療市場：按疾病類型

  • 概述
    • 市場規模和預測
  • 霍奇金淋巴瘤
    • 主要市場趨勢、增長因素、增長機會
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 非霍奇金淋巴瘤
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 5 章淋巴瘤治療市場：按治療類型

  • 概述
    • 市場規模和預測
  • 免疫治療
    • 主要市場趨勢、增長因素、增長機會
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 化療
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 靶向治療
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 放射治療
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 6 章淋巴瘤治療市場：按給藥途徑

  • 概述
    • 市場規模和預測
  • 口服給藥途徑
    • 主要市場趨勢、增長因素、增長機會
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 注射
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 7 章淋巴瘤治療市場：按分銷渠道

  • 概述
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長因素和增長機會
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 零售藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 網上藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 8 章：淋巴瘤治療市場：按地區

  • 概述
    • 市場規模和預測：按地區劃分
  • 北美
    • 主要趨勢和機遇
    • 市場規模和預測：按疾病類型劃分
    • 市場規模和預測：按治療類型劃分
    • 市場規模和預測：按管理途徑劃分
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 美國
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 加拿大
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 墨西哥
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模和預測：按疾病類型劃分
    • 市場規模和預測：按治療類型劃分
    • 市場規模和預測：按管理途徑劃分
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 德國
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 法國
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 英國
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 意大利
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 西班牙
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模和預測：按疾病類型劃分
    • 市場規模和預測：按治療類型劃分
    • 市場規模和預測：按管理途徑劃分
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 日本
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 中國
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 澳大利亞
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 印度
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 韓國
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 亞太地區其他地區
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模和預測：按疾病類型劃分
    • 市場規模和預測：按治療類型劃分
    • 市場規模和預測：按管理途徑劃分
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 巴西
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 南非
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模/預測：按給藥途徑
      • 市場規模和預測：按分銷渠道劃分
      • 其他地區
      • 主要市場趨勢、增長因素、增長機會
      • 市場規模和預測：按疾病類型劃分
      • 市場規模和預測：按治療類型劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分

第 9 章競爭格局

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競賽儀表板
  • 比賽熱圖
  • 2022 年頂級公司定位

第 10 章公司簡介

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Seagen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
Product Code: A01129

The Lymphoma Therapeutics Market is valued for $15,691.45 million in 2022 and is estimated to reach $35,207.45 million by 2032, exhibiting a CAGR of 8.4% from 2023 to 2032. Lymphoma is a type of cancer that affects the lymphatic system, which is a part of the immune system that helps to fight infections and other diseases. Lymphomas arise when certain types of white blood cells called lymphocytes undergo abnormal changes and begin to grow and multiply uncontrollably. Lymphoma therapeutics refers to various types of treatments that are used to treat lymphoma. Some of the various types of lymphoma therapeutics can include chemotherapy, radiation therapy, immunotherapy, targeted therapy, stem cell transplantation, and sometimes surgery.

Lymphoma Therapeutics Market - IMG1

The key factor that drives the growth of the lymphoma therapeutics market is the growing pipeline of lymphoma therapeutics. For instance, according to GlobalData report in March 2023, larotrectinib sulfate by Bayer AG is under clinical development and currently in phase II for non-Hodgkin lymphoma. The phase II drugs for non-Hodgkin lymphoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into phase III.

Moreover, significant rise in prevalence of lymphoma and surge in geriatric population notably contribute toward the growth of the market. Furthermore, increase in investment in R&D activities and favorable government policies for the approval of novel drugs to treat non-Hodgkin and Hodgkin lymphoma are expected to open new avenues for the growth of the global market during the forecast period.

However, the high cost of available treatments and lack of awareness about lymphoma and availability of different options to treat lymphoma among people hamper the market growth. Conversely, surge in geriatric population which is more susceptible to lymphoma and development of effective medicines that are accessible and safe for patients are expected to provide lucrative opportunity for the growth of the market during the forecast period.

The lymphoma therapeutics market is segmented into disease type, treatment type, route of administration, distribution channel, and region. By disease type, the market is bifurcated into Hodgkin lymphoma and non-Hodgkin lymphoma. On the basis of treatment type, it is fragmented into immune therapy, chemotherapy, targeted therapy, and radiation therapy. Depending on the route of administration, the market is categorized into oral route and injectables. As per distribution channel, it is segregated into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America garnered the maximum share of the lymphoma therapeutics market share in 2022 and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of non-Hodgkin lymphoma in the region and surge in awareness among the population regarding the available diagnostic technologies and treatment alternatives for lymphoma. Furthermore, availability of reimbursement policies and surge in number of clinical trials owing to rise in investment by key market players in R&D activities are expected to fuel the market growth.

Asia-Pacific is expected to register the fastest CAGR during the forecast period owing to rise in geriatric population and strong pipeline of lymphoma drugs in developing countries. Furthermore, increase in prevalence of lymphoma and rise in awareness about treatment options available for lymphoma in the developing countries such as India, China, and South Korea contribute toward the growth of the market in this region.

The key players that operate in the lymphoma therapeutics market are: AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lily and Company, F Hoffman La Roche Ltd, Johnson & Johnson, Gilead Sciences, Inc., Seagen Inc., Teva Pharmaceutical Industries Ltd., and Pfizer Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lymphoma therapeutics market analysis from 2022 to 2032 to identify the prevailing lymphoma therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the lymphoma therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global lymphoma therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma

By Treatment Type

  • Immune Therapy
  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy

By Route of Administration

  • Oral Route
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Seagen Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Surge in prevalence of lymphoma
      • 3.4.1.2. Increase in number of drugs in pipeline
      • 3.4.1.3. Rise in number of clinical trials
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of available treatment
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in developing economies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Hodgkin Lymphoma
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Non-Hodgkin Lymphoma
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Immune Therapy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Chemotherapy
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Targeted Therapy
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Radiation Therapy
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Oral Route
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Injectable
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Retail Pharmacies
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Online Pharmacies
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: LYMPHOMA THERAPEUTICS MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key trends and opportunities
    • 8.2.2. Market size and forecast, by Disease Type
    • 8.2.3. Market size and forecast, by Treatment Type
    • 8.2.4. Market size and forecast, by Route of Administration
    • 8.2.5. Market size and forecast, by Distribution Channel
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Key market trends, growth factors and opportunities
      • 8.2.6.1.2. Market size and forecast, by Disease Type
      • 8.2.6.1.3. Market size and forecast, by Treatment Type
      • 8.2.6.1.4. Market size and forecast, by Route of Administration
      • 8.2.6.1.5. Market size and forecast, by Distribution Channel
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Key market trends, growth factors and opportunities
      • 8.2.6.2.2. Market size and forecast, by Disease Type
      • 8.2.6.2.3. Market size and forecast, by Treatment Type
      • 8.2.6.2.4. Market size and forecast, by Route of Administration
      • 8.2.6.2.5. Market size and forecast, by Distribution Channel
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Key market trends, growth factors and opportunities
      • 8.2.6.3.2. Market size and forecast, by Disease Type
      • 8.2.6.3.3. Market size and forecast, by Treatment Type
      • 8.2.6.3.4. Market size and forecast, by Route of Administration
      • 8.2.6.3.5. Market size and forecast, by Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key trends and opportunities
    • 8.3.2. Market size and forecast, by Disease Type
    • 8.3.3. Market size and forecast, by Treatment Type
    • 8.3.4. Market size and forecast, by Route of Administration
    • 8.3.5. Market size and forecast, by Distribution Channel
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Key market trends, growth factors and opportunities
      • 8.3.6.1.2. Market size and forecast, by Disease Type
      • 8.3.6.1.3. Market size and forecast, by Treatment Type
      • 8.3.6.1.4. Market size and forecast, by Route of Administration
      • 8.3.6.1.5. Market size and forecast, by Distribution Channel
      • 8.3.6.2. France
      • 8.3.6.2.1. Key market trends, growth factors and opportunities
      • 8.3.6.2.2. Market size and forecast, by Disease Type
      • 8.3.6.2.3. Market size and forecast, by Treatment Type
      • 8.3.6.2.4. Market size and forecast, by Route of Administration
      • 8.3.6.2.5. Market size and forecast, by Distribution Channel
      • 8.3.6.3. UK
      • 8.3.6.3.1. Key market trends, growth factors and opportunities
      • 8.3.6.3.2. Market size and forecast, by Disease Type
      • 8.3.6.3.3. Market size and forecast, by Treatment Type
      • 8.3.6.3.4. Market size and forecast, by Route of Administration
      • 8.3.6.3.5. Market size and forecast, by Distribution Channel
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Key market trends, growth factors and opportunities
      • 8.3.6.4.2. Market size and forecast, by Disease Type
      • 8.3.6.4.3. Market size and forecast, by Treatment Type
      • 8.3.6.4.4. Market size and forecast, by Route of Administration
      • 8.3.6.4.5. Market size and forecast, by Distribution Channel
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Key market trends, growth factors and opportunities
      • 8.3.6.5.2. Market size and forecast, by Disease Type
      • 8.3.6.5.3. Market size and forecast, by Treatment Type
      • 8.3.6.5.4. Market size and forecast, by Route of Administration
      • 8.3.6.5.5. Market size and forecast, by Distribution Channel
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Key market trends, growth factors and opportunities
      • 8.3.6.6.2. Market size and forecast, by Disease Type
      • 8.3.6.6.3. Market size and forecast, by Treatment Type
      • 8.3.6.6.4. Market size and forecast, by Route of Administration
      • 8.3.6.6.5. Market size and forecast, by Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key trends and opportunities
    • 8.4.2. Market size and forecast, by Disease Type
    • 8.4.3. Market size and forecast, by Treatment Type
    • 8.4.4. Market size and forecast, by Route of Administration
    • 8.4.5. Market size and forecast, by Distribution Channel
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Key market trends, growth factors and opportunities
      • 8.4.6.1.2. Market size and forecast, by Disease Type
      • 8.4.6.1.3. Market size and forecast, by Treatment Type
      • 8.4.6.1.4. Market size and forecast, by Route of Administration
      • 8.4.6.1.5. Market size and forecast, by Distribution Channel
      • 8.4.6.2. China
      • 8.4.6.2.1. Key market trends, growth factors and opportunities
      • 8.4.6.2.2. Market size and forecast, by Disease Type
      • 8.4.6.2.3. Market size and forecast, by Treatment Type
      • 8.4.6.2.4. Market size and forecast, by Route of Administration
      • 8.4.6.2.5. Market size and forecast, by Distribution Channel
      • 8.4.6.3. Australia
      • 8.4.6.3.1. Key market trends, growth factors and opportunities
      • 8.4.6.3.2. Market size and forecast, by Disease Type
      • 8.4.6.3.3. Market size and forecast, by Treatment Type
      • 8.4.6.3.4. Market size and forecast, by Route of Administration
      • 8.4.6.3.5. Market size and forecast, by Distribution Channel
      • 8.4.6.4. India
      • 8.4.6.4.1. Key market trends, growth factors and opportunities
      • 8.4.6.4.2. Market size and forecast, by Disease Type
      • 8.4.6.4.3. Market size and forecast, by Treatment Type
      • 8.4.6.4.4. Market size and forecast, by Route of Administration
      • 8.4.6.4.5. Market size and forecast, by Distribution Channel
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Key market trends, growth factors and opportunities
      • 8.4.6.5.2. Market size and forecast, by Disease Type
      • 8.4.6.5.3. Market size and forecast, by Treatment Type
      • 8.4.6.5.4. Market size and forecast, by Route of Administration
      • 8.4.6.5.5. Market size and forecast, by Distribution Channel
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Key market trends, growth factors and opportunities
      • 8.4.6.6.2. Market size and forecast, by Disease Type
      • 8.4.6.6.3. Market size and forecast, by Treatment Type
      • 8.4.6.6.4. Market size and forecast, by Route of Administration
      • 8.4.6.6.5. Market size and forecast, by Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key trends and opportunities
    • 8.5.2. Market size and forecast, by Disease Type
    • 8.5.3. Market size and forecast, by Treatment Type
    • 8.5.4. Market size and forecast, by Route of Administration
    • 8.5.5. Market size and forecast, by Distribution Channel
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Key market trends, growth factors and opportunities
      • 8.5.6.1.2. Market size and forecast, by Disease Type
      • 8.5.6.1.3. Market size and forecast, by Treatment Type
      • 8.5.6.1.4. Market size and forecast, by Route of Administration
      • 8.5.6.1.5. Market size and forecast, by Distribution Channel
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Key market trends, growth factors and opportunities
      • 8.5.6.2.2. Market size and forecast, by Disease Type
      • 8.5.6.2.3. Market size and forecast, by Treatment Type
      • 8.5.6.2.4. Market size and forecast, by Route of Administration
      • 8.5.6.2.5. Market size and forecast, by Distribution Channel
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Key market trends, growth factors and opportunities
      • 8.5.6.3.2. Market size and forecast, by Disease Type
      • 8.5.6.3.3. Market size and forecast, by Treatment Type
      • 8.5.6.3.4. Market size and forecast, by Route of Administration
      • 8.5.6.3.5. Market size and forecast, by Distribution Channel
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Key market trends, growth factors and opportunities
      • 8.5.6.4.2. Market size and forecast, by Disease Type
      • 8.5.6.4.3. Market size and forecast, by Treatment Type
      • 8.5.6.4.4. Market size and forecast, by Route of Administration
      • 8.5.6.4.5. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Bayer AG
    • 10.1.1. Company overview
    • 10.1.2. Key Executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
  • 10.2. Bristol-Myers Squibb Company
    • 10.2.1. Company overview
    • 10.2.2. Key Executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
    • 10.2.7. Key strategic moves and developments
  • 10.3. Eli Lilly and Company
    • 10.3.1. Company overview
    • 10.3.2. Key Executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
    • 10.3.7. Key strategic moves and developments
  • 10.4. Johnson & Johnson
    • 10.4.1. Company overview
    • 10.4.2. Key Executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
  • 10.5. Gilead Sciences, Inc.
    • 10.5.1. Company overview
    • 10.5.2. Key Executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
    • 10.5.7. Key strategic moves and developments
  • 10.6. Seagen Inc.
    • 10.6.1. Company overview
    • 10.6.2. Key Executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
    • 10.6.7. Key strategic moves and developments
  • 10.7. Teva Pharmaceutical Industries Ltd.
    • 10.7.1. Company overview
    • 10.7.2. Key Executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
    • 10.7.6. Business performance
    • 10.7.7. Key strategic moves and developments
  • 10.8. Pfizer Inc.
    • 10.8.1. Company overview
    • 10.8.2. Key Executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
    • 10.8.7. Key strategic moves and developments
  • 10.9. AstraZeneca
    • 10.9.1. Company overview
    • 10.9.2. Key Executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
    • 10.9.7. Key strategic moves and developments
  • 10.10. F. Hoffmann-La Roche Ltd.
    • 10.10.1. Company overview
    • 10.10.2. Key Executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance
    • 10.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 02. LYMPHOMA THERAPEUTICS MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. LYMPHOMA THERAPEUTICS MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 05. LYMPHOMA THERAPEUTICS MARKET FOR IMMUNE THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. LYMPHOMA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. LYMPHOMA THERAPEUTICS MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. LYMPHOMA THERAPEUTICS MARKET FOR RADIATION THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 10. LYMPHOMA THERAPEUTICS MARKET FOR ORAL ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. LYMPHOMA THERAPEUTICS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 13. LYMPHOMA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. LYMPHOMA THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. LYMPHOMA THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. LYMPHOMA THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 22. U.S. LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 23. U.S. LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 24. U.S. LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 25. U.S. LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. CANADA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 27. CANADA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. CANADA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 29. CANADA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. UK LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 48. UK LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 49. UK LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 50. UK LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ITALY LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 52. ITALY LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 53. ITALY LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 54. ITALY LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 60. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 61. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 64. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 68. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 69. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 70. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. CHINA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 73. CHINA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 74. CHINA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 75. CHINA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 76. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 77. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 78. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 79. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. INDIA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 81. INDIA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 82. INDIA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 83. INDIA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 88. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 89. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 90. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 92. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 93. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 94. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 97. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 98. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 99. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 101. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 102. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 103. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 104. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 105. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 106. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 107. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 108. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 109. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 110. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 111. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 112. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 113. BAYER AG: KEY EXECUTIVES
  • TABLE 114. BAYER AG: COMPANY SNAPSHOT
  • TABLE 115. BAYER AG: PRODUCT SEGMENTS
  • TABLE 116. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 117. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 118. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 119. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 120. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 121. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
  • TABLE 122. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 123. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 124. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 125. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 126. ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 127. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 128. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 129. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 130. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 131. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 132. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 133. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 134. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 135. GILEAD SCIENCES, INC.: KEY STRATERGIES
  • TABLE 136. SEAGEN INC.: KEY EXECUTIVES
  • TABLE 137. SEAGEN INC.: COMPANY SNAPSHOT
  • TABLE 138. SEAGEN INC.: PRODUCT SEGMENTS
  • TABLE 139. SEAGEN INC.: PRODUCT PORTFOLIO
  • TABLE 140. SEAGEN INC.: KEY STRATERGIES
  • TABLE 141. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 142. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 143. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 144. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 145. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 146. PFIZER INC.: KEY EXECUTIVES
  • TABLE 147. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 148. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 149. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 150. PFIZER INC.: KEY STRATERGIES
  • TABLE 151. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 152. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 153. ASTRAZENECA: PRODUCT SEGMENTS
  • TABLE 154. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 155. ASTRAZENECA: KEY STRATERGIES
  • TABLE 156. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 157. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 158. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 159. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 160. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. LYMPHOMA THERAPEUTICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF LYMPHOMA THERAPEUTICS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN LYMPHOMA THERAPEUTICS MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALLYMPHOMA THERAPEUTICS MARKET
  • FIGURE 10. LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR NON-HODGKIN LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR IMMUNE THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR TARGETED THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR RADIATION THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR ORAL ROUTE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR INJECTABLE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. LYMPHOMA THERAPEUTICS MARKET BY REGION, 2022
  • FIGURE 26. U.S. LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. CANADA LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. MEXICO LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. GERMANY LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. FRANCE LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. UK LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. ITALY LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SPAIN LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. JAPAN LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. CHINA LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. INDIA LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. BRAZIL LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49. COMPETITIVE DASHBOARD
  • FIGURE 50. COMPETITIVE HEATMAP: LYMPHOMA THERAPEUTICS MARKET
  • FIGURE 51. TOP PLAYER POSITIONING, 2022
  • FIGURE 52. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. BRISTOL-MYERS SQUIBB COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 58. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. GILEAD SCIENCES, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 63. SEAGEN INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 64. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. ASTRAZENECA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 73. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)